|1.||Higashiyama, Shigeki: 2 articles (05/2003 - 01/2002)|
|2.||Yagita, H: 2 articles (11/2000 - 08/2000)|
|3.||Kataoka, Hiromi: 1 article (06/2008)|
|4.||Joh, Takashi: 1 article (06/2008)|
|5.||Sasaki, Makoto: 1 article (06/2008)|
|6.||Kubota, Eiji: 1 article (06/2008)|
|7.||Ogasawara, Naotaka: 1 article (06/2008)|
|8.||Tanida, Satoshi: 1 article (06/2008)|
|9.||Shimura, Takaya: 1 article (06/2008)|
|10.||Sugahara, Kazuki N: 1 article (02/2004)|
08/01/2000 - "These results suggest that KB-R7785 could be a potent therapeutic agent for GVHD, and indicate the beneficial effects of KB-R7785 that inhibit tumor infiltration and prevent acute GVHD while preserving the GVL effect of allogeneic BMT."
03/15/1999 - "The fact that KB-R7785 interferes with early steps of angiogenesis and cancer spread suggests that MMP inhibitors may control both primary and secondary tumor growths by limiting the expansion of endothelial cells, as well as cancer cells, composing the tumors."
03/15/1999 - "KB-R7785 rendered centrally avascular tumors with only a rim of peripheral neovasculature, which had significant lower functional vascular density and vascular area than the corresponding parameters in control tumors 10 days after inoculation [79.9+/-6.7 cm/cm2 versus 164.1+/-10.1 cm/cm2 (P < 0.01) and 19.8+/-1.5% versus 42.6+/-2.7% (P < 0.01), respectively]. "
03/15/1999 - "Tumors grown in controls have doubled their area in 3.3 days, whereas those treated by KB-R7785 progressed almost four times slower (tumor area doubling time, 12 days). "
03/15/1999 - "In vivo, KB-R7785 administrated twice daily for 15 days (100 mg/kg, i.p.), starting the day of tumor inoculation (5 x 10(5) C26 cells) in transparent chamber, has resulted in 88.2% suppression of tumor growth, compared with that in vehicle-administered mice (controls). "
|2.||Brain Ischemia (Cerebral Ischemia)
06/01/2001 - "These results indicate that KB-R7785 has a protective efficacy against focal cerebral ischemia, and our data provide further evidence that MMP-9 contributes to brain infarct formation."
06/01/2001 - "The authors examined the effect of MMP inhibitor KB-R7785 on brain infarct formation resulting from permanent focal cerebral ischemia in mice. "
06/01/2001 - "Matrix metalloproteinase inhibitor KB-R7785 attenuates brain damage resulting from permanent focal cerebral ischemia in mice."
|3.||Stomach Neoplasms (Stomach Cancer)
|5.||Type 2 Diabetes Mellitus (MODY)
|1.||heparin-binding EGF-like growth factor (HB-EGF)
|3.||Epidermal Growth Factor (EGF)
|4.||Blood Glucose (Blood Sugar)
|5.||Tissue Inhibitor of Metalloproteinase-2
|6.||von Willebrand Factor
|7.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|9.||DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)
|2.||Bone Marrow Transplantation (Transplantation, Bone Marrow)